AIGH Capital Management LLC Has $4.22 Million Stock Position in PolyPid Ltd. $PYPD

AIGH Capital Management LLC grew its position in PolyPid Ltd. (NASDAQ:PYPD) by 27.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,194,108 shares of the company’s stock after buying an additional 253,727 shares during the period. PolyPid makes up 1.9% of AIGH Capital Management LLC’s portfolio, making the stock its 21st largest position. AIGH Capital Management LLC owned approximately 11.72% of PolyPid worth $4,215,000 at the end of the most recent quarter.

PolyPid Trading Down 2.4%

Shares of NASDAQ PYPD opened at $3.27 on Monday. The firm has a market cap of $51.99 million, a PE ratio of -0.85 and a beta of 1.50. PolyPid Ltd. has a 1-year low of $2.30 and a 1-year high of $3.93. The company has a fifty day moving average price of $3.41 and a 200 day moving average price of $3.22.

PolyPid (NASDAQ:PYPD) last announced its earnings results on Wednesday, August 13th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.25). Equities research analysts forecast that PolyPid Ltd. will post -1.79 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Roth Capital reissued a “buy” rating on shares of PolyPid in a report on Thursday, August 14th. Craig Hallum reissued a “buy” rating and issued a $13.00 price target (down previously from $15.00) on shares of PolyPid in a report on Thursday, August 14th. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a report on Friday, September 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of PolyPid in a report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of PolyPid in a report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.40.

PolyPid Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.